| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Original Article |
1 Department of Surgery, National Cancer Institute, Via Venezian, 1, 20133, Milan, Italy
2 Department of Pathology, National Cancer Institute, Milan, Italy
3 Department of Medical Oncology, National Cancer Institute, Milan, Italy
4 Department of Surgery, Centre Hospitalier de l’Université de Montreal, University of Montreal Health Center, Montreal, Canada
5 Department of Obstetrics & Gynaecology, School of Medical Science, State University of Campinas, Campinas, Brazil
Correspondence: Address correspondence and reprint requests to: Marcello Deraco, MD; E-mail: marcello.deraco{at}istitutotumori.mi.it.
Background: Diffuse malignant peritoneal mesothelioma (DMPM) is a subset of peritoneal mesothelioma with a poor clinical outcome. We performed a prognostic analysis in a cohort of DMPM patients treated homogeneously by cytoreductive surgery and intraperitoneal hyperthermic perfusion (IPHP).
Methods: Forty-nine DMPM patients who underwent 52 consecutive procedures were enrolled onto the study. Cytoreductive surgery was performed according to the peritonectomy technique, and the IPHP was performed with cisplatin plus doxorubicin or cisplatin plus mitomycin C. We assessed the correlation of the clinicopathologic variables (previous surgical score, age, sex, performance status, previous systemic chemotherapy, carcinomatosis extension, completeness of cytoreduction, IPHP drug schedule, mitotic count [MC], nuclear grade, and biological markers [epidermal growth factor receptor, p16, matrix metalloproteinase 2 and matrix metalloproteinase 9]) with overall and progression-free survival.
Results: The mean age was 52 years (range, 22–74 years). The mean follow-up was 20.3 months (range, 1–89 months). Regarding the biological markers, the rates of immunoreactivity of epidermal growth factor receptor, p16, matrix metalloproteinase 2, and matrix metalloproteinase 9 were 94%, 60%, 100%, and 85%, respectively. The strongest factors influencing overall survival were completeness of cytoreduction and MC, whereas those for progression-free survival were performance status and MC. No biological markers were shown to be of prognostic value.
Conclusions: Completeness of cytoreduction, performance status, and MC seem to be the best determinants of outcome. These data warrant confirmation by a further prospective formal trial. No biological markers presented a significant correlation with the outcome. The overexpression of epidermal growth factor receptor, matrix metalloproteinase 2, and matrix metalloproteinase 9 and absent or reduced expression of p16 might be related to the underlining tumor kinetics of DMPM and warrant further investigation with other methods.
Key Words: Peritoneal mesothelioma • Locoregional therapy • Prognosis • Biological markers
This article has been cited by other articles:
 |
|
 |
|
  J. M. Foster, Z. Gatalica, S. Lilleberg, G. Haynatzki, and B. W. Loggie Novel and Existing Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor are Predictors of Optimal Resectability in Malignant Peritoneal Mesothelioma Ann. Surg. Oncol., January 1, 2009; 16(1): 152 - 158. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. LATERZA, S. KUSAMURA, D. BARATTI, G. D. OLIVA, and M. DERACO Role of Explorative Laparoscopy to Evaluate Optimal Candidates for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients with Peritoneal Mesothelioma In Vivo, January 1, 2009; 23(1): 187 - 190. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Villa, M. G. Daidone, R. Motta, L. Venturini, C. De Marco, A. Vannelli, S. Kusamura, D. Baratti, M. Deraco, A. Costa, et al. Multiple Mechanisms of Telomere Maintenance Exist and Differentially Affect Clinical Outcome in Diffuse Malignant Peritoneal Mesothelioma Clin. Cancer Res., July 1, 2008; 14(13): 4134 - 4140. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Baratti, S. Kusamura, D. Nonaka, G. D. Oliva, B. Laterza, and M. Deraco Multicystic and Well-differentiated Papillary Peritoneal Mesothelioma Treated by Surgical Cytoreduction and Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) Ann. Surg. Oncol., October 1, 2007; 14(10): 2790 - 2797. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. D. Yan, M. Links, S. Fransi, T. Jacques, D. Black, V. Saunders, and D. L. Morris Learning Curve for Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Peritoneal Surface Malignancy A Journey to Becoming a Nationally Funded Peritonectomy Center Ann. Surg. Oncol., August 1, 2007; 14(8): 2270 - 2280. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Lim, J. N. Cormier, B. W. Feig, P. F. Mansfield, R. S. Benjamin, J. R. Griffin, J. L. Chase, P. W. T. Pisters, R. E. Pollock, and K. K. Hunt Toxicity and Outcomes Associated with Surgical Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Patients with Sarcomatosis Ann. Surg. Oncol., August 1, 2007; 14(8): 2309 - 2318. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. D. Yan, J. Sim, and D. L. Morris Selection of Patients with Colorectal Peritoneal Carcinomatosis for Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy Ann. Surg. Oncol., June 1, 2007; 14(6): 1807 - 1817. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Yan, L Welch, D Black, and P. Sugarbaker A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma Ann. Onc., May 1, 2007; 18(5): 827 - 834. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. D. Yan, G. Edwards, R. Alderman, C. E. Marquardt, and P. H. Sugarbaker Morbidity and Mortality Assessment of Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Diffuse Malignant Peritoneal Mesothelioma--A Prospective Study of 70 Consecutive Cases Ann. Surg. Oncol., February 1, 2007; 14(2): 515 - 525. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
